• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于定量测定人血浆中依诺肝素的抗活化因子X(抗Xa)检测方法的研究。

Investigation of an anti-activated factor X (anti-Xa) assay for the quantification of enoxaparin in human plasma.

作者信息

Al-Sallami Hesham S, Medlicott Natalie J

机构信息

School of Pharmacy, University of Otago, Dunedin, New Zealand.

出版信息

J Pharm Pharmacol. 2015 Feb;67(2):209-14. doi: 10.1111/jphp.12333. Epub 2014 Dec 31.

DOI:10.1111/jphp.12333
PMID:25557692
Abstract

OBJECTIVES

Enoxaparin is a low-molecular weight heparin (LMWH) widely used for the treatment of thrombosis and measured through a chromogenic assay (anti-Xa). The aim of this project was to investigate the impact of patient and sampling sources of variation on an anti-Xa assay for enoxaparin.

METHODS

COATEST was used in accordance with manufacturer's instructions. A standard curve of LMWH concentration (0.1-1.0 IU/ml) was prepared. The shelf-life and freeze-thaw stability of Xa over a 6-month period were investigated. The effects of blood sample haemolysis and plasma antithrombin-III (AT) concentration were examined.

KEY FINDINGS

The standard curve performed well with high accuracy (average bias of 8.1%) and precision (average CV of 2.8%). The shelf-life of Xa once reconstituted could be extended from 1 month to 4 months if aliquots were frozen at -20°C. Some loss of anti-Xa activity was observed on freeze-thawing (bias up to 25%). Haemolysis of 2.5% was found to interfere with the assay. AT level as low as 50% did not affect assay accuracy.

CONCLUSIONS

Xa standards when frozen immediately after reconstitution could be used for the following 4 months. Haemolysis interferes with the assay, but a 50% reduction in AT does not significantly affect the assay result.

摘要

目的

依诺肝素是一种广泛用于治疗血栓形成的低分子肝素(LMWH),通过显色测定法(抗Xa)进行检测。本项目旨在研究患者和样本来源的变异对依诺肝素抗Xa测定的影响。

方法

按照制造商的说明使用COATEST。制备了低分子肝素浓度(0.1 - 1.0 IU/ml)的标准曲线。研究了Xa在6个月期间的保质期和冻融稳定性。检查了血样溶血和血浆抗凝血酶III(AT)浓度的影响。

主要发现

标准曲线表现良好,具有高精度(平均偏差8.1%)和精密度(平均CV为2.8%)。如果将分装物在-20°C冷冻,Xa复溶后的保质期可从1个月延长至4个月。冻融时观察到抗Xa活性有一些损失(偏差高达25%)。发现2.5%的溶血会干扰测定。低至50%的AT水平不会影响测定准确性。

结论

Xa标准品复溶后立即冷冻可在接下来的4个月内使用。溶血会干扰测定,但AT降低50%不会显著影响测定结果。

相似文献

1
Investigation of an anti-activated factor X (anti-Xa) assay for the quantification of enoxaparin in human plasma.用于定量测定人血浆中依诺肝素的抗活化因子X(抗Xa)检测方法的研究。
J Pharm Pharmacol. 2015 Feb;67(2):209-14. doi: 10.1111/jphp.12333. Epub 2014 Dec 31.
2
Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.剖宫产术后的血栓预防——三种低分子量肝素(达肝素、依诺肝素和替扎肝素)抗血栓特性的比较
Thromb Haemost. 2001 Dec;86(6):1374-8.
3
Variability of plasma anti-Xa activities with different lots of enoxaparin.不同批次依诺肝素的血浆抗Xa活性的变异性。
Ann Pharmacother. 2004 Apr;38(4):563-8. doi: 10.1345/aph.1D245. Epub 2004 Feb 24.
4
Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms.住院体重小于 55 公斤患者依诺肝素预防治疗后的抗 Xa 活性。
Thromb Res. 2013;132(6):761-4. doi: 10.1016/j.thromres.2013.10.005. Epub 2013 Oct 12.
5
Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.回顾性评价新生儿和婴儿接受依诺肝素治疗血栓时补充抗凝血酶 III 的效果。
Pediatr Blood Cancer. 2014 Jun;61(6):1063-7. doi: 10.1002/pbc.24899. Epub 2013 Dec 20.
6
Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.对肾病患者急性冠脉综合征使用依诺肝素时的抗Xa监测
Ann Pharmacother. 2004 Oct;38(10):1576-81. doi: 10.1345/aph.1E096. Epub 2004 Aug 24.
7
Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins.普通肝素与低分子量肝素(依诺肝素)与血浆蛋白的非特异性结合比较。
Thromb Haemost. 1993 Oct 18;70(4):625-30.
8
Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.10名健康志愿者中两种低分子量肝素的生物活性比较。
Br J Clin Pharmacol. 1995 Dec;40(6):577-84.
9
Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays.新型荧光法抗 FXa 检测与两种商业抗 FXa 显色法的抗凝反应比较。
Thromb Res. 2011 Dec;128(6):e166-70. doi: 10.1016/j.thromres.2011.08.002. Epub 2011 Aug 27.
10
Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.依诺肝素单次推注用于慢性血液透析的安全性和有效性。一项上市后开放性研究的结果
Kidney Blood Press Res. 2004;27(4):211-7. doi: 10.1159/000079866. Epub 2004 Jul 20.

引用本文的文献

1
Establishment and validation of a method for determining anti-Xa factor potency of enoxaparin sodium.依诺肝素钠抗Xa因子效价测定方法的建立与验证
PeerJ. 2025 May 6;13:e19437. doi: 10.7717/peerj.19437. eCollection 2025.
2
Validation study on the assay method for anti-factor IIa potency of enoxaparin sodium.依诺肝素钠抗因子IIa活性测定方法的验证研究
PeerJ. 2024 Dec 18;12:e18732. doi: 10.7717/peerj.18732. eCollection 2024.
3
Pharmacokinetics, distribution, and excretion of sodium oligomannate, a recently approved anti-Alzheimer's disease drug in China.
中国近期获批的抗阿尔茨海默病药物寡聚甘露糖酸钠的药代动力学、分布及排泄情况。
J Pharm Anal. 2022 Feb;12(1):145-155. doi: 10.1016/j.jpha.2021.06.001. Epub 2021 Jun 5.
4
A New Test for the Detection of Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in the Emergency Room Setting.一种用于在急诊室环境中检测直接口服抗凝剂(利伐沙班和阿哌沙班)的新测试。
Crit Care Explor. 2019 Aug 20;1(8):e0024. doi: 10.1097/CCE.0000000000000024. eCollection 2019 Aug.
5
Pharmacokinetic and Tissue Distribution of Fucoidan from after Oral Administration to Rats.口服褐藻糖胶后在大鼠体内的药代动力学和组织分布。
Mar Drugs. 2018 Apr 18;16(4):132. doi: 10.3390/md16040132.